BVI to launch new SERENITY and SERENITY Toric monofocal IOLs

News
Article

The new, non-diffractive IOLs are the second generation of BVI’s ISOPURE premium monofocal IOL that was launched in 2019.

Doctor performing cataract surgery Image credit: AdobeStock/Kate

Image credit: AdobeStock/Kate

Ophthalmic device company BVI has announced that its new SERENITY and SERENITY Toric premium monofocal IOLs will be fully commercial available in CE-accepting markets in 2025.1 The new, non-diffractive IOLs are the second generation of BVI’s ISOPURE premium monofocal IOL that was launched in 2019, according to a news release.

“As we launch the second-generation SERENITY and SERENITY Toric IOLs, BVI views this IOL as potentially a game-changer when it comes to standard of care for monofocal procedures,” said Shervin Korangy, president and CEO of BVI, in the release. “Our portfolio includes a wide range of IOLs, meticulously designed from material to haptics to optics to provide the optimal outcome without the burden of retro-fitting legacy predicate devices.”

The IOL also features ISOFOCAL optic technology to aid in clear distance vision and intermediate vision by balancing depth of focus and image quality. This allows the lens to provide far vision equal to a monofocal but with adequate intermediate vision up to 66 cm. Additionally, the lens’ double c-loop POD platform is specifically designed to deliver precise astigmatism correction and stable IOL positioning, according to the release. Those with astigmatism benefit with stability in the capsular bag, which results in outcomes accurately predicted by BVI’s toric calculator.1

The SERENITY series’ ISOFOCAL technology also works in favor of stability by delivering spherical aberration correction across the entire optic diameter and customizable levels of spherical aberration per dioptric power, the release said.

Sheraz Daya, MD, FACP, FACS, FRCS(Ed), FRCOphth, of Centre For Sight, UK, was 1 of the first surgeons to implant SERENITY. “It is wonderful to see this increased range of focus lens on the same platform as the Finevision with 4 C loop haptics,” he said in the release. “I look forward to the Toric version as well which I know will be very stable with no rotation.”

BVI plans to launch the new IOL during the 2024 European Society of Cataract and Refractive Surgeons meeting in Fira de Barcelona, Spain from September 6-10.

Reference:
  1. BVI to launch new SERENITY and SERENITY toric premium monofocal IOLs. News release. BVI. September 3, 2024. Accessed September 4, 2024. https://www.bvimedical.com/us/bvi-to-launch-new-serenity-and-serenity-toric-premium-monofocal-iols/
Recent Videos
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
Brianna Rhue, OD, FAAO, FSLS, reviewed key takeaways from The Future of Myopia Management: Perspectives from Leading Experts talk from SECO 2025.
Dr. Julie Rodman discusses retina, imaging, and posterior segment in SECO presentations
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Three EnVision Summit faculty members weigh in on the importance of comanagement in glaucoma management, where artificial intelligence will lead eye care, and what hopes are on the horizon for corneal ectasia treatments.
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.
John Berdahl, MD, overviews the new FYXS Ocular Pressure Adjusting Pump and HERCULES trial at the Glaucoma 360 meeting.
© 2025 MJH Life Sciences

All rights reserved.